News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alexion's Soliris® (eculizumab) Receives Marketing Approval in Canada for Patients With Atypical HUS


3/6/2013 10:01:07 AM

ONTARIO, March 6, 2013 /CNW/ - Alexion Pharma Canada., a subsidiary of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that Canada's national healthcare regulatory agency, Health Canada, has approved the use of SolirisĀ® (eculizumab) for the treatment of patients with atypical hemolytic uremic syndrome (atypical HUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Atypical HUS, or aHUS, is a life-threatening and chronic ultra-rare, genetic disease that progressively damages vital organs, leading to stroke, heart attack, kidney failure and death.1

Read at Canada NewsWire

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES